Kerin N Z, Faitel K, Kerin I A, Quinones L, Stomel R J
Department of Medicine, Section of Cardiovascular Diseases, Sinai-Grace Hospital and Wayne State University, School of Medicine, Detroit, MI, USA.
Am J Ther. 2000 Aug;7(4):245-50. doi: 10.1097/00045391-200007040-00004.
The efficacy and safety of low-dose amiodarone (Cordarone; Wyeth-Ayerst, Philadelphia, PA) was assessed in 62 symptomatic patients with paroxysmal atrial fibrillation who were resistant to at least two types of IA drugs. The beneficial response to this treatment was defined as a reduction in paroxysmal atrial fibrillation of greater than or equal to 50% within 1 month. Of the 42 patients (67.7%) who were responders, 39 (62.9%) were completely free of episodes. Intolerable side effects were seen in 12 patients (19.3%). Tolerable side effects were encountered by 73% of patients. Most of the adverse effects were transient and responded to a reduction in the dose. In conclusion, (1) low-dose amiodarone produces a beneficial response in the prevention of paroxysmal atrial fibrillation, and (2) low-dose amiodarone is well tolerated.
对62例症状性阵发性心房颤动患者进行了低剂量胺碘酮（可达龙；惠氏-艾尔斯特公司，宾夕法尼亚州费城）疗效和安全性的评估，这些患者对至少两种IA类药物耐药。该治疗的有益反应定义为1个月内阵发性心房颤动减少大于或等于50%。在42例有反应的患者（67.7%）中，39例（62.9%）完全无发作。12例患者（19.3%）出现难以耐受的副作用。73%的患者出现可耐受的副作用。大多数不良反应是短暂的，减少剂量后即可缓解。总之，（1）低剂量胺碘酮在预防阵发性心房颤动方面产生有益反应，（2）低剂量胺碘酮耐受性良好。
